SCHEMBL6178418

SCHEMBL6178418

COC(=O)c1cc(Cl)c(N)n2cc(-c3ccccc3)nc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
KDM4E B2RXH2 3/20 0.45
RAB9A P51151 2/20 0.45
NPC1 O15118 1/20 0.45
ALDH1A3 P47895 2/20 0.44
ALDH1A2 O94788 1/20 0.44
TP53 P04637 1/20 0.42
PLA2G2A P14555 1/20 0.42
HPGD P15428 4/20 0.41
GAA P10253 3/20 0.41
MAPT P10636 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
ADORA2A P29274 1/20 0.41
HSD17B10 Q99714 2/20 0.40
USP2 O75604 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6178995 0.87 DHODH (0.48) KDM4ERAB9ANPC1MAPTADORA2A
SCHEMBL5889428 0.80 HTR3A (0.55) ALDH1A1KDM4ERAB9ANPC1HPGD
SCHEMBL6177033 0.77 GAA (0.44) ALDH1A1KDM4ETP53GAAMAPT
SCHEMBL5889440 0.77 GAA (0.44) ALDH1A1KDM4EGAAMAPTADCY10
SCHEMBL6179337 0.76 GAA (0.43) ALDH1A1KDM4ETP53PLA2G2AHPGD
SCHEMBL27801681 0.71 ALDH1A1 (0.48) ALDH1A1KDM4EPLA2G2AHPGDGAA
SCHEMBL6179085 0.71 GAA (0.48) ALDH1A1KDM4EGAAMAPT
SCHEMBL14836765 0.70 DHODH (0.71) ALDH1A1KDM4ERAB9ANPC1ALDH1A3
SCHEMBL6176173 0.70 HTR3A (0.47) ALDH1A1KDM4ERAB9ANPC1HPGD
SCHEMBL25290589 0.70 ALDH1A1 (0.49) ALDH1A1KDM4EALDH1A3ALDH1A2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1440071-B1 IMIDAZOPYRIDINE COMPOUNDS AS 5-HT 4? RECEPTOR MODULATORS PFIZER (US) 2005-10-26 EP disclosed
US-20040034226-A1 Imidazopyridine compounds as 5-HT4 receptor modulators UCHIDA CHIKARA (JP) 2004-02-19 US disclosed
US-6624162-B2 5-HT4 receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, Functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. PFIZER INC. 2003-09-23 US disclosed
US-20030092699-A1 Imidazopyridine compounds as 5-HT4 receptor modulators PFIZER INC. 2003-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092699-A1 Imidazopyridine compounds as 5-HT4 receptor modulators HTR4, HRH4, HRH2 ALDH1A1 2581/4885KDM4E 2141/4885RAB9A 421/4885
US-20040034226-A1 Imidazopyridine compounds as 5-HT4 receptor modulators HRH4, HTR4, HRH2 ALDH1A1 2238/4885KDM4E 1796/4885RAB9A 471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.